Page 3 - Topline Results News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Longboard Pharmaceuticals, Inc Announces Positive Topline Data from the Pacific Study, a Phase 1b/2a Clinical Trial, for Bexicaserin in Participants with Developmental and Epileptic Encephalopathies

Longboard Pharmaceuticals, Inc Announces Positive Topline Data from the Pacific Study, a Phase 1b/2a Clinical Trial, for Bexicaserin in Participants with Developmental and Epileptic Encephalopathies
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesEncephalopathies deesLongboard pharmaceuticals incLongboard pharmaceuticalsEpileptic encephalopathiesTopline resultsEfficacy dataSafety data

Longboard Pharmaceuticals Announces Positive Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial, for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs)

Bexicaserin achieved a median seizure reduction of 53.3% in countable motor seizures compared to 20.8% in the placebo group across the DEE study population A median seizure reduction of 72.1% in.

United statesRandall kayeEncephalopathies deesTracy dixon salazarKevinr lindDennis dlugosEpilepsy study consortiumLongboard pharmaceuticals incExchange commissionLongboard pharmaceuticalsEpileptic encephalopathiesTopline resultsEfficacy dataSafety dataChief medicalExecutive director

Longboard Pharmaceuticals (LBPH) Reports Positive Topline Data from the PACIFIC Study

Longboard Pharmaceuticals (LBPH) Reports Positive Topline Data from the PACIFIC Study
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesEncephalopathies deesDennis dlugosRandall kayeTracy dixon salazarKevinr lindLongboard pharmaceuticals incEpilepsy study consortiumLongboard pharmaceuticalsEpileptic encephalopathiesTopline resultsEfficacy dataSafety dataChief medicalExecutive directorVice president

Cytokinetics Announces Positive Results From SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy -December 27, 2023 at 07:31 am EST

Statistically Significant and Clinically Meaningful Increasein Primary Efficacy Endpoint at 24 Weeks of Treatment; Improvement Consistent Across All Prespecified Subgroups Statistically Significant.

United statesFadyi malikDiane weiserMartin maronTufts university school of medicineExchange commissionUs food drug administrationGlobenewswire incCytokinetics incorporated nasdaqNational medical products administrationCytokinetics incorporatedCorporate communicationsResearch developmentSymphony healthClinical trials programHypertrophic cardiomyopathy center

Cytokinetics to Host Investor Call on December 27 to Discuss the Topline Results from

SOUTH SAN FRANCISCO, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of its senior management will host an investor call at 8:30 AM

United statesDiane weiserJournal of the american college cardiologySymphony healthCorporate communicationsCytokinetics incorporated nasdaqExchange commissionQuantitative understandingObstruction impactTopline resultsPrivate securities litigation reform actSafe harborVice presidentHeart failureClaims data dofClinically diagnosed hypertrophic cardiomyopathy